DSV DSV Panalpina A/S

DSV, 1045 - UPGRADE OF FINANCIAL OUTLOOK FOR 2023

DSV, 1045 - UPGRADE OF FINANCIAL OUTLOOK FOR 2023

Company Announcement No. 1045

For the first six months of 2023, DSV achieved revenue of DKK 78,681 million (DKK 123,874 million in H1 2022), gross profit of DKK 22,722 million (DKK 26,955 million in H1 2022) and EBIT before special items of DKK 9,377 million (DKK 13,949 million in H1 2022).

Based on the performance in the first six months of 2023 and our expectations for the second half of 2023, we upgrade the full-year outlook for 2023 as follows:

  • EBIT before special items is expected to be in the range of DKK 17,000-18,500 million (previously DKK 16,000-18,000 million).
  • The effective tax rate of the Group is expected to be approximately 25.0% (previously 24.0%).

We assume a gradual recovery in global trade volumes and that there will be no significant worsening of the global economic environment in the second half of 2023.

As the global logistics markets continue to normalise, we expect a further decline in gross profit yields for air and sea compared to the H1-23 levels.

For Road and Solutions, we expect that markets will be flat or decline slightly in H2 2023.

We assume that the currency exchange rates, especially the USD/DKK rate, will remain at the current levels.

As the geopolitical and macroeconomic environment remains uncertain, unforeseen changes may impact our financial results.

DSV publishes its H1 2023 interim financial report on 25 July 2023.

Contacts

Investor Relations: Flemming Ole Nielsen, tel. ,

Media: Christian Krogslund, tel. ,

Yours sincerely,

DSV A/S

 

Attachment



EN
25/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DSV Panalpina A/S

 PRESS RELEASE

DSV – H1 2025 analyst conference call

DSV – H1 2025 analyst conference call We expect to release the H1 2025 interim results of DSV A/S in the morning of 31 July 2025. A webcast and conference call will be held at 11:00 am CEST.At the conference call, Jens H. Lund, Group CEO, and Michael Ebbe, Group CFO, will present the H1 2025 Interim Financial Report. The presentation will be followed by a Q&A session. Date:                 31 July 2025Time:                 11:00 am CEST To attend the webcast presentation, please go to or go to . If you wish to ask questions during the conference call, please register through this link: ...

ABGSC Shipping & Transport Research ... (+2)
  • ABGSC Shipping & Transport Research
  • Mikkel Kousgaard Rasmussen

DSV AS: 1 director

A director at DSV AS bought 320 shares at 1,560.860DKK and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...

 PRESS RELEASE

DSV, 1156 - MANAGER’S TRANSACTIONS IN DSV A/S SHARES

DSV, 1156 - MANAGER’S TRANSACTIONS IN DSV A/S SHARES Company Announcement No. 1156 DSV A/S hereby provides notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transaction related to shares in DSV A/S made by a manager. ContactsInvestor RelationsStig Frederiksen, tel. , Alexander Plenborg, tel. , Yours sincerely,DSV A/S Attachment

Jacob Berg Nielsen
  • Jacob Berg Nielsen

DSV (Buy, TP: DKK1750.00) - Unique earnings story unfolding

While Q1 EBIT beat consensus and DSV stand-alone guidance was maintained amid tariff concerns, the preliminary above-consensus Schenker cost synergies was the main positive. We still view DSV as an idiosyncratic earnings growth story with upside potential from hard-to-quantify commercial synergies. We reiterate our BUY, and have raised our target price to DKK1,750 (1,700) on the better-than-expected cost synergies.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch